Acuitive
OperatingAcuitive Technologies, Inc.
Biotech · Allendale, NJ
Acuitive’s Citregen® aims to reshape orthopedic surgery with an FDA-cleared family of devices that promote tissue regeneration by increasing cell energy. Trusted by Stryker Corporation, with 8,000+ successful implants, we’re scaling to launch 6 more FDA-cleared products in a $10B+ market. With multiple launches planned for 2025-2026, we believe we’re poised for growth.*
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Apr 30, 2026| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Series A Preferred Stockpreferred | 3,381,084 | 1 | 40.0% | — |
| Common Stock | 5,065,951 | 1 | 60.0% | $7.20Sep 2025 |
| Total | 8,447,035 | 100% |
Principal holders% as the filing states it, Apr 30, 2026
- Alex I. Khowaylo887,646 Common Stock14.8%of
Sold to the crowd
- Reg CF · Sep 202563,265 shares at $7.20$455.5K· 132 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
10 people
Has built the operations, manufacturing and financial functions as co-founder in multiple companies over the past thirty years bringing new material and product concepts addressing real clinical needs in the orthopedic marketplace.
Former CEO of Becton Dickinson, brings executive and board governance experience.
Show 1 more personShow fewer
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 1 annual reports (FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGAR- Form DSep 24, 20260001864239-26-000004EDGAR
- Form C-ARApr 30, 20260001864239-26-000001EDGAR
- Form C-UDec 30, 20250001864239-25-000008EDGAR
- Form C/ADec 5, 20250001864239-25-000007EDGAR
- Form C/ANov 3, 20250001864239-25-000005EDGAR
- Form CSep 30, 20250001864239-25-000004EDGAR
- Form DDec 8, 20230001864239-23-000002EDGAR
- Form DJun 6, 20230001864239-23-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.